A Novel Solid Phase Technology for High-Throughput Gene Synthesis
2008; Future Science Ltd; Volume: 45; Issue: 3 Linguagem: Inglês
10.2144/000112953
ISSN1940-9818
AutoresJan Brülle, Markus Fischer, Thomas Langmann, Gudrun Horn, Thomas A. Waldmann, Stefan Arnold, Markus Fuhrmann, Octavian Schatz, Tim O’Connell, Daniela O’Connell, Alexandra Auckenthaler, Heinz Schwer,
Tópico(s)Advanced biosensing and bioanalysis techniques
ResumoBioTechniquesVol. 45, No. 3 Application Forum - Sponsored PaperOpen AccessA novel solid phase technology for high-throughput gene synthesisJan Van den Brulle†, Markus Fischer†, Thomas Langmann†, Gudrun Horn, Thomas Waldmann, Stefan Arnold, Markus Fuhrmann, Octavian Schatz, Tim O'Connell, Daniela O'Connell, Alexandra Auckenthaler & Heinz SchwerJan Van den Brulle†Sloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany, Markus Fischer†Institut für Biochemie und Lebensmittelchemie, Universität Hamburg, Grindelallee 117, 20146 Hamburg, Germany, Thomas Langmann†Institut für Humangenetik, Universität Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany, Gudrun HornSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany, Thomas WaldmannSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany, Stefan ArnoldSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany, Markus FuhrmannSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany, Octavian SchatzSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany, Tim O'ConnellSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany, Daniela O'ConnellSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany, Alexandra AuckenthalerSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, Germany & Heinz Schwer*To whom correspondence should be addressed: Tel: +49 89 80 90 95 0; Fax: +49 89 80 90 95 50; Email: E-mail Address: h.schwer@sloning.deSloning BioTechnology GmbH, Zeppelinstr. 4, 82178 Puchheim, GermanyPublished Online:16 May 2018https://doi.org/10.2144/000112953AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit IntroductionNovel technological developments in high-throughput DNA sequencing yield a plethora of sequence information from a steadily increasing number of species. This rapidly growing sequence information provides the basis for enhanced DNA-engineering methods, which has recently culminated in the complete chemical synthesis of a 582 kb Mycoplasma genitalium genome (1). Other important applications for de novo gene synthesis in biomedical research and biotechnology range from the cloning of individual genes to the development of synthetic DNA vaccines (2), vectors for gene therapy (3), and gene libraries for protein engineering and molecular evolution (4).The majority of currently used gene synthesis methods rely on the enzymatic assembly of chemically synthesized complementary oligonucleotides via stepwise or multiplexed polymerase cycling assembly (PCA). PCA-based methods are intrinsically error-prone due to the high error rate associated with oligonucleotide synthesis and sequence mutations introduced during PCR amplification (5). Several improvements for error reduction have been introduced, including approaches with mismatch cleaving endonucleases, exonuclease treatment, selection of failure DNA products with DNA-mismatch binding proteins, and functional screening of cloned constructs. Nevertheless, reduced synthesis quality with heterogenous products is still a major problem of conventional PCA methods.Less frequently used non-PCA methods (5) include the annealing and ligation reaction, gene synthesis via one strand, insertion gene synthesis, template directed ligation, the ligase chain reaction, and microarray-based multiplex oligonucleotide synthesis. These non-PCA synthesis methods avoid sequence errors from PCR reactions and have less restrictions in DNA sequence design. However, these techniques also rely on target-specific high quality de novo oligonucleotide synthesis and several manual reaction steps, and are therefore often cumbersome, time-consuming, and expensive. Here, we describe a novel ligation-based strategy for chemical gene synthesis using the Sloning building block technology, Slonomics®.Outline of the Slonomics® TechnologyIn our method, a defined number of standardized building blocks is chemically synthesized as single-stranded oligonucleotides containing self-complementary regions. Intra-strand base pairing of these regions leads to the formation of a stable hairpin-like secondary structure comprising a short loop of four nucleotides, a double-stranded stem region assuring the stability of the molecule, and a three-nucleotide single-stranded overhang (Fig. 1). Two different classes of building blocks are defined as "splinkers" and "anchors." All splinker molecules share the same scaffold structure and differ only in their variable three-base single-stranded overhangs. In contrast, the anchor oligonucleotides differ in the overhang and also in the directly adjacent base triplet (Fig. 1).Figure 1. The principal reaction schemes used in the elongation, starting with the library containing double-stranded DNA building blocks, i.e. 4096 (46) anchors and 64 (43) splinkers. Small sub-fragments (elongation blocks) of specific target sequence are generated through repeated reaction cycles of ligation, immobilization, washing, and restriction.In order to create a library representing all possible permutations, 64 (43) different splinkers and 4096 (46) different anchor oligonucleotides are required. Each anchor molecule harbors an additional biotin modification in the loop region, allowing the oligonucleotide to be coupled to a streptavidin-coated surface with high affinity. The two types of oligonucleotides are further characterized by the presence of different recognition sites for type IIS restriction enzymes within their stem regions (Fig. 1). The anchor oligonucleotide contains a recognition site for Eam 1104I (CTCTTC[1/4], generating a three-base overhang) and the corresponding splinker molecule harbors a recognition site for Esp3I (CGTCTC[1/5], generating a four-base overhang).To construct a large double-stranded DNA fragment from these molecular building blocks, the sequence is first assembled as smaller sub-fragments of 18 bp. These so-called "elongation blocks" can be synthesized in parallel reactions. In the first step, one anchor and one splinker molecule are ligated via hybridization (Watson-Crick base pairing) of complementary single-stranded overhangs. Generally, this step is performed in solution, since enzymatic reactions in solution occur at much faster rates than those on solid supports, where diffusion pathways are much longer. Following ligation, the resulting product is immobilized on a streptavidin-coated 96-well plate via the biotin modification of the anchor molecule. Non-reacted material is removed in a washing step. The remaining surface-bound ligation products are subsequently cleaved by Eam1104I, which is specific for the anchor that donates the base triplet block (Fig. 1). The cleavage of the ligation product by this restriction enzyme releases an elongated, highly pure "intermediate product" that has a new three-base single-stranded overhang and serves as an acceptor for the next anchor molecule. Thus, this reaction cycle results in the incorporation of three new bases to the growing chain and a shortened anchor that remains bound to the surface. This reaction cycle is repeated five times to produce an 18 bp DNA fragment. For optimal reaction performance, the anchor molecules and the intermediate products should be present in equimolar concentrations. If one of the ligation partners is in excess, resulting in a mixture of correct, immobilized higher level ligation products and unreacted precursors, unligated intermediate products can be removed efficiently by washing, while unligated anchors remain bound to the surface after cleavage.As depicted in Figure 2, the complete synthesis process comprises two distinct phases. During the initial "elongation" phase, short sub-sequences of the target molecule are produced as described above, resulting in individual elongation blocks with 18 independently definable base pairs. Since many of these reactions can be performed in parallel, the entire target sequence is already constructed during the initial elongation process, albeit as a series of short sub-fragments. In the second reaction phase, the socalled "transposition," the pre-assembled elongation blocks are connected in a pair-wise fashion after each block has been cleaved with the appropriate type IIS restriction enzyme (Fig. 2). Restriction with Eam1104I results in the release of the elongation block from the surface and thereby generates a three-base overhang. Cleavage with Esp3I removes the splinker-component of the molecule, leading to a four-base overhang. The resulting molecules can be assembled in a highly selective manner due to the different length and specific sequences of their overhangs.Figure 2. Synthesis of larger fragments (transposition). In the transposition phase, individual elongation blocks are assembled to form the full-length gene constructs, again through repeated reaction cycles of ligation, washing, and restriction.Additionally, depending on the restriction by Eam1104I, the ligation reactions can be performed at the solid surface or in solution, which allows for the focus to be on either product purity or yield. Since the resulting molecules still harbor the constant anchor and splinker regions at their terminal ends, this reaction cycle (including washing steps) can be repeated several times, each round resulting in DNA molecules that have doubled in length with respect to those of the previous round. At different transposition stages, the resulting constructs are "harvested" from the solid surface by cleavage and transferred from the automated production platform to a second standardized system for the final assembly and quality control. Each transposition can be developed robustly up to the T5 level (5 transposition rounds), corresponding to a fragment length of 462 bp. If necessary, these "T5-building blocks" can be further assembled by standard recombinant DNA technology.The Slonomics® technology is also highly efficient and cost-effective. In contrast to classical strategies, where each oligonucleotide is individually designed and used for a single synthesis reaction, our building blocks are used for multiple reactions over the course of several synthesis projects. In addition, all steps of the process can be done in parallel, which allows for the simultaneous production of several gene constructs and enables the transfer of every working step to a robotic platform (Fig. 3A). The complete synthesis is performed in multi-well plates, and hardware components with demonstrated suitability for robust production processes have been combined in an entirely computer-controlled system. This permits the fully-automated synthesis of any 462 bp DNA fragment, from design to end product, within a time frame of 44 hours (Fig. 3B).Figure 3. The synthesis process as implemented on an industrial-style robotic platform. (A) Robotic platform. Each box represents a separate work station. E, elongation platform; T, transposition platform; P, oligonucleotide pipetting platform. Each of these stations is present twice. QC, quality control. The stations are connected via a fully automatic clockwise rotating conveyor belt, which transports the micro-well plates to the relevant positions. Additionally, a refrigerator for the storage of enzymes is implemented in the platform. The stock & gate station is designed for the storage and exchange of microwell plates. (B) Work flow for the synthesis of a T5 fragment.Construction of the GC-rich Shadow of Prion Protein Gene (SPRN)Since our synthesis strategy is not based on the hybridization of single-stranded overlapping oligonucleotides, DNA sequences posing a challenge for classical PCA and non-PCA based synthesis technologies, for example, those with extremely high or low GC content, or those harboring direct repeats, can be constructed without difficulty on our platform. As an example, we performed a de novo synthesis of the 456 bp open reading frame of the very GC-rich (79%) human shadow of prion protein gene (SPRN, Accession number BC040198). We first extracted the DNA sequence of the SPRN gene from GenBank and applied our automatic software for building block selection. In the initial step of gene assembly, 32 elongation blocks with 18 separately defined nucleotides were synthesized. Extension of splinkers by successive ligation steps gave rise to single bands without contaminating side products. The individual elongation blocks of SPRN were then subjected to 5 transposition reactions, resulting in 32, 61, 118, 233, and 462 bp products. The complete synthetic gene was then cloned into a plasmid, and fully correct clones were identified by sequencing.Materials and methodsOligonucleotidesHairpin oligonucleotides with three nucleotide 5′-overhangs representing the complete set of building blocks (4096 (46) anchors and 64 (43) splinkers) were synthesized by Operon Biotechnologies GmbH (Köln, Germany) in a 10 µmol scale. Anchor oligonucleotides are biotinylated and contain a recognition site for Eam1104I, whereas splinker molecules harbor a recognition site for Esp3I. All oligonucleotides were assessed for purity, binding efficiency, ligation efficiency, and effectiveness of cleavage by restriction enzymes.Streptavidin-coated 96-well platesStreptavidin-coated 96-well plates were developed in collaboration with Microcoat (Bernried, Germany). The plate surface was optimized for high DNA-binding capacity and highly efficient and reproducible enzymatic reactions. Therefore, the plates were coated with a three-dimensional matrix containing cross-linked streptavidin.Elongation of building blocksAll reactions were carried out in 96-well plates in a total volume of 150 µl. The initial ligation step was performed with 10 U of T4-DNA-Ligase (Fermentas, St. Leon-Rot, Germany) in 1× Tango™ buffer (Fermentas) with 120 pmol splinker and 100 pmol anchor for 15 min at room temperature. The resulting product was then bound to the streptavidincoated surface of a 96-well plate and incubated for 15 min at RT with constant shaking at 1300 rpm. After removal of the unbound fraction by washing with washing buffer (33 mM Tris-acetate, 10 mM Mg-acetate, 66 mM K-acetate), the elongated product was released by cleavage with 10 U Eam1104I in 1× Tango™ buffer for 90 min at 37°C. The enzyme was then heat inactivated for 10 min at 65°C, and the supernatant with the elongated splinker was transferred to a fresh uncoated well. Subsequently, the next anchor molecule with the appropriate overhang was added for a new cycle of elongation. After the last elongation step, the final product was controlled for purity and yield by polyacrylamide gel electrophoresis.Transposition of elongation blocksAll reactions were carried out in a total volume of 150 µl. The synthesized elongation blocks were cleaved with Esp3I only (for blocks remaining bound to streptavidin), or with Eam1104I and Esp3I simultaneously (for soluble blocks), for 90 min in 1× Tango™ buffer at 37°C with 30 U of each restriction enzyme. After thermal inactivation of enzymes, the cleaved molecules were ligated to each other in a pairwise fashion via their three nucleotide and four nucleotide overhangs, respectively. This reaction step was carried out five times to result in a T5 product with a size of 462 bp. The DNA product was then cloned and verified by sequencing. These modules are subsequently assembled into larger products using classical recombinant techniques.Building block selection and process control softwareA proprietary algorithm and software package (implemented using JAVA EE 5 SDK, Sun Microsystems, Santa Clara, CA, and Eclipse as IDE) was developed for optimized decomposition of any target nucleotide sequence into a list of building blocks. At both termini of the target sequence, customized sequence extensions were introduced by default to achieve the necessary length for automated synthesis. The fully integrated system also runs the robotic platform for automated synthesis of standardized fragments up to 462 bp. The design process takes into account the following criteria: (i) avoidance of self-complementary four-base overhangs during the transposition, (ii) analysis of the target sequence with respect to the occurrence of Eam1104I and Esp3I restriction sites and implementation of appropriate alternative strategies (e.g., use of other outside cutters or methylated anchors), and (iii) optional optimization of the target sequence in terms of codon usage, GC-content, or other technical requirements.ConclusionThe superior performance of the Slonomics® technology compared to classical gene synthesis methods is based on several factors. Firstly, unlike long, single-stranded oligonucleotides, the DNA building blocks used for our method are consistently of high quality due to their short lengths (27 and 33 nucleotides, respectively) and their essentially identical structure, for which the phosphoramidite synthesis procedure has been optimally adjusted. Secondly, given that they are designed to form double-stranded structures based on their self-complementing sequence, common problems resulting from the tendency for single-stranded oligonucleotides to form unwanted secondary structures are avoided. Finally, the oligonucleotides are produced simultaneously and in large scale and are used in synthesis reactions only after having passed comprehensive quality tests. The setup described here can be employed in many molecular biological applications, for example, tailor-made solutions for optimal gene expression and simultaneous production of individual gene variants. In addition, this technological advance enables the precisely controlled synthesis of highly diverse mutant libraries that can be screened for modified proteins with specific functional properties.ContactSloning BioTechnology GmbHZeppelinstr. 4, 82178 Puchheim, GermanyTel: +49 89 80 90 95 0 Fax: +49 89 80 90 95 50Email: h.schwer@sloning.dewww.sloning.deAcknowledgmentsWe thank Annette Arbter, Bernadette Gut, Stefan Heiderich, Bettina Herold, Stephanie Keberle, Michael Kieven, Meika Mader, and Andrea Sterner for skillful assistance. We gratefully acknowledge Nils Hinrichsen for editorial assistance, Ralf Strohner for critical discussions and comments, and Stefan Kiefl for support in software programming.References1. Gibson, D.G., G.A. Benders, C. Andrews-Pfannkoch, E.A. Denisova, H. Baden-Tillson, J. Zaveri, T.B. Stockwell, A. Brownley, D.W. Thomas, M.A. Algire, et al.. 2008. Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome. Science 319:1215–1220.Crossref, Medline, CAS, Google Scholar2. Rice, J., C.H. Ottensmeier, and F.K. Stevenson. 2008. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 8:108–120.Crossref, Medline, CAS, Google Scholar3. Meyer, M. and E. Wagner. 2006. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum. Gene Ther. 17:1062–1076.Crossref, Medline, CAS, Google Scholar4. Neylon, C. 2004. Chemical and biochemical strategies for the randomization of protein encoding DNA sequences: library construction methods for directed evolution. Nucleic Acids Res. 32:1448–1459.Crossref, Medline, CAS, Google Scholar5. Xiong, A.S., R.H. Peng, J. Zhuang, J.G. Liu, F. Gao, J.M. Chen, Z.M. Cheng, and Q.H. Yao. 2008. Non-polymerase-cycling-assembly-based chemical gene synthesis: strategies, methods, and progress. Biotechnol. Adv. 26:121–134.Crossref, Medline, CAS, Google ScholarPatents6. Schatz, O., Method for the synthesis of DNA fragments. 2006, European Patent EP 1181395Google Scholar7. Schatz, O., O'Connell, T. Nucleic acid linkers and their use in gene synthesis. 2003, European Patent EP1314783Google Scholar8. Schatz, O., O'Connell, T., Schwer, H., Waldmann, T. Method for the manufacture of nucleic acid molecules. 2004, European Patent EP1411122Google ScholarFiguresReferencesRelatedDetailsCited ByA Vaccinia-based system for directed evolution of GPCRs in mammalian cells30 March 2023 | Nature Communications, Vol. 14, No. 1Nondegenerate Saturation Mutagenesis: Library Construction and Analysis via MAX and ProxiMAX Randomization22 June 2022Protein Engineering: Advances in Phage Display for Basic Science and Medical Research31 January 2022 | Biochemistry (Moscow), Vol. 87, No. S1A novel framework for engineering protein loops exploring length and compositional variation28 April 2021 | Scientific Reports, Vol. 11, No. 1The evolving art of creating genetic diversity: From directed evolution to synthetic biologyBiotechnology Advances, Vol. 50Cell-free Directed Evolution of a Protease in Microdroplets at Ultrahigh Throughput27 January 2021 | ACS Synthetic Biology, Vol. 10, No. 2Split & mix assembly of DNA libraries for ultrahigh throughput on-bead screening of functional proteins8 May 2020 | Nucleic Acids Research, Vol. 48, No. 11Phage Display Libraries for Antibody Therapeutic Discovery and Development23 August 2019 | Antibodies, Vol. 8, No. 3Cognizance of Molecular Methods for the Generation of Mutagenic Phage Display Antibody Libraries for Affinity Maturation15 April 2019 | International Journal of Molecular Sciences, Vol. 20, No. 8Efficient Construction and Effective Screening of Synthetic Domain Antibody Libraries14 February 2019 | Methods and Protocols, Vol. 2, No. 1Solid-Phase Gene Synthesis for Mutant Library Construction: The Future of Directed Evolution?13 September 2018 | ChemBioChem, Vol. 19, No. 19Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies14 December 2017 | mAbs, Vol. 10, No. 2Monoclonal Antibody Generation by Phage DisplayPhage display and selection of lanthipeptides on the carboxy-terminus of the gene-3 minor coat protein15 November 2017 | Nature Communications, Vol. 8, No. 1The Polymerase Step Reaction (PSR) Method for Gene and Library Synthesis27 September 2016Whole Cell Panning with Phage Display3 March 2017Antibody Phage Display17 March 2018Beyond the Natural ProteomeHigh-Resolution Phenotypic Landscape of the RNA Polymerase II Trigger Loop29 November 2016 | PLOS Genetics, Vol. 12, No. 11Gene Mutagenesis Methods17 September 2016Synthetic approach to the generation of antibody diversityBMB Reports, Vol. 48, No. 9Gene and library synthesis without amplification: polymerase step reaction (PSR)Zhuo-Bin Lee, Christopher Firnhaber, Jesse Clarke & Brian S. DeDecker3 April 2018 | BioTechniques, Vol. 59, No. 3Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)10 May 2015 | Journal of Peptide Science, Vol. 21, No. 8Codon-Precise, Synthetic, Antibody Fragment Libraries Built Using Automated Hexamer Codon Additions and Validated through Next Generation Sequencing15 May 2015 | Antibodies, Vol. 4, No. 2Speeding up Directed Evolution: Combining the Advantages of Solid-Phase Combinatorial Gene Synthesis with Statistically Guided Reduction of Screening Effort23 July 2014 | ACS Synthetic Biology, Vol. 4, No. 3Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein–protein interactionsDaniel Baxter, Christopher G Ullman & Jody M Mason22 December 2014 | Future Medicinal Chemistry, Vol. 6, No. 18Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions30 April 2014 | Protein Engineering, Design and Selection, Vol. 27, No. 10Characterization and screening of IgG binding to the neonatal Fc receptor7 April 2014 | mAbs, Vol. 6, No. 4Combinatorial Optimization of Cystine-Knot Peptides towards High-Affinity Inhibitors of Human Matriptase-111 October 2013 | PLoS ONE, Vol. 8, No. 10ProxiMAX randomization: a new technology for non-degenerate saturation mutagenesis of contiguous codons23 September 2013 | Biochemical Society Transactions, Vol. 41, No. 5Stability and solubility engineering of the EphB4 tyrosine kinase catalytic domain using a rationally designed synthetic library8 July 2013 | Protein Engineering Design and Selection, Vol. 26, No. 10Library methods for structural biology of challenging proteins and their complexesCurrent Opinion in Structural Biology, Vol. 23, No. 3Comprehensive Interrogation of a Minimalist Synthetic CDR-H3 Library and Its Ability to Generate Antibodies with Therapeutic PotentialJournal of Molecular Biology, Vol. 425, No. 10A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties27 October 2014 | mAbs, Vol. 5, No. 3Humanization of Antibodies Using Heavy Chain Complementarity-determining Region 3 Grafting Coupled with in Vitro Somatic HypermutationJournal of Biological Chemistry, Vol. 288, No. 11Combinatorial Design of an Anticalin Directed against the Extra-Domain B for the Specific Targeting of Oncofetal FibronectinJournal of Molecular Biology, Vol. 425, No. 4Maximizing Detergent Stability and Functional Expression of a GPCR by Exhaustive Recombination and EvolutionJournal of Molecular Biology, Vol. 422, No. 3Directed Evolution of Enzymes20 April 2012Directed Evolution Strategies for Enantiocomplementary Haloalkane Dehalogenases: From Chemical Waste to Enantiopure Building Blocks23 November 2011 | ChemBioChem, Vol. 13, No. 1AnticalinsPhage Display23 May 2012HuCAL PLATINUM, a Synthetic Fab Library Optimized for Sequence Diversity and Superior Performance in Mammalian Expression SystemsJournal of Molecular Biology, Vol. 413, No. 1Synthetic Antibodies Designed on Natural Sequence LandscapesJournal of Molecular Biology, Vol. 412, No. 1Conserved Stress-protective Activity between Prion Protein and ShadooJournal of Biological Chemistry, Vol. 286, No. 11Gerichtete Evolution stereoselektiver Enzyme: Eine ergiebige Katalysator‐Quelle für asymmetrische Reaktionen16 August 2010 | Angewandte Chemie, Vol. 123, No. 1Laboratory Evolution of Stereoselective Enzymes: A Prolific Source of Catalysts for Asymmetric Reactions16 August 2010 | Angewandte Chemie International Edition, Vol. 50, No. 1Industrial Scale Gene SynthesisGene Synthesis – Enabling Technologies for Synthetic Biology3 April 2011Engineering of an Orthogonal Aminoacyl-tRNA Synthetase for Efficient Incorporation of the Non-natural Amino Acid O-Methyl-L-tyrosine using Fluorescence-based Bacterial Cell SortingJournal of Molecular Biology, Vol. 404, No. 1Sustainable Processes Based on Enzymes Enabling 100% Yield and 100% ee Concepts5 October 2010Microbial systems engineering: First successes and the way ahead9 March 2010 | BioEssays, Vol. 32, No. 4De Novo Metabolic Engineering and the Promise of Synthetic DNA26 February 2010Genome engineering9 December 2009 | Nature Biotechnology, Vol. 27, No. 12Library Construction For Protein Engineering8 March 2010 Vol. 45, No. 3 Follow us on social media for the latest updates Metrics History Published online 16 May 2018 Published in print September 2008 Information© 2008 Future Science LtdAcknowledgmentsWe thank Annette Arbter, Bernadette Gut, Stefan Heiderich, Bettina Herold, Stephanie Keberle, Michael Kieven, Meika Mader, and Andrea Sterner for skillful assistance. We gratefully acknowledge Nils Hinrichsen for editorial assistance, Ralf Strohner for critical discussions and comments, and Stefan Kiefl for support in software programming.PDF download
Referência(s)